Ricardo D Gonzalez

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 5

Top Topics

Long Noncoding Rna

Monoclonal Antibody

Top Venues

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

George W Small, Farida S Akhtari, Adrian J Green, Tammy M Havener, Michael Sikes, Julia Coelho França Quintanilha, Ricardo D Gonzalez, David M Reif, Alison A Motsinger-Reif, Howard L McLeod, Tim Wiltshire
Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy. Cells 12 (12) (2023)
George W Small, Farida S Akhtari, Adrian J Green, Tammy M Havener, Michael Sikes, Julia Coelho França Quintanilha, Ricardo D Gonzalez, David M Reif, Alison A Motsinger-Reif, Howard L McLeod, Tim Wiltshire
Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy. Cells 12 (12) (2023)
Ricardo D Gonzalez, George W Small, Adrian J Green, Farida S Akhtari, Tammy M Havener, Julia Coelho França Quintanilha, Amber B Cipriani, David M Reif, Howard L McLeod, Alison A Motsinger-Reif, Tim Wiltshire
RYK Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients. Pharmaceuticals (Basel, Switzerland) 16 (5) (2023)
Ricardo D Gonzalez, George W Small, Adrian J Green, Farida S Akhtari, Alison A Motsinger-Reif, Julia Coelho França Quintanilha, Tammy M Havener, David M Reif, Howard L McLeod, Tim Wiltshire
MKX-AS1 Gene Expression Associated with Variation in Drug Response to Oxaliplatin and Clinical Outcomes in Colorectal Cancer Patients. Pharmaceuticals (Basel, Switzerland) 16 (5) (2023)
George W Small, Farida S Akhtari, Adrian J Green, Tammy M Havener, Michael Sikes, Julia Coelho França Quintanilha, Ricardo D Gonzalez, David M Reif, Alison A Motsinger-Reif, Howard L McLeod, Tim Wiltshire
Pharmacogenomic Analyses Implicate B Cell Developmental Status and MKL1 as Determinants of Sensitivity toward Anti-CD20 Monoclonal Antibody Therapy. Cells 12 (12) (2023)